Skip to main content
Premium Trial:

Request an Annual Quote

FDA Panel to Meet About Epigenomics' PMA for Colorectal Cancer Test

NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel is tentatively set to meet in four months to discuss Epigenomics’ colorectal cancer screening test, the company said today.

FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on March 25, 2014 over Epigenomics’ premarket approval submission for its Epi proColon test. The company completed its submission in January, and in February, FDA granted Epigenomics’ application priority review status.

Earlier this month, the company announced flat revenues for its third quarter.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.